Program
MT1013
A development code. Also written as “[14C] MT1013/MT1013 Injection”, “Single ascending doses of MT1013” and “Multiple ascending doses of MT1013”.
Its studies are mostly in Hyperparathyroidism, Secondary, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shaanxi Micot Pharmaceutical Technology | 41 open or running | phase 3since Aug 1, 2025 | Nov 13, 2024 | Nov 26, 2026phase 3 · NCT07122401 |
| Shaanxi Micot Technology | 21 open or running | phase 2since May 8, 2025 | Feb 20, 2021 | none ahead |
Also a collaborator on its studies: wcct-global.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 20, 2021First study: phase 1 study in Healthy VolunteerNew to Shaanxi Micot TechnologyShaanxi Micot Technology · NCT04783090 · 40 enrolled · United States
- Nov 13, 2024Shaanxi Micot Pharmaceutical Technology's first study: phase 2 study in Hyperparathyroidism, SecondaryNew to Shaanxi Micot Pharmaceutical TechnologyShaanxi Micot Pharmaceutical Technology · NCT06690242 · 115 enrolled · China
- Dec 18, 2024Phase 2 study in Hyperparathyroidism, SecondaryShaanxi Micot Pharmaceutical Technology · NCT06747247 · 98 enrolled · China
- May 8, 2025Phase 2 study in Hyperparathyroidism, SecondaryShaanxi Micot Technology · NCT06976177 · 310 planned · China
- Aug 1, 2025Phase 3 study in Hyperparathyroidism, SecondaryShaanxi Micot Pharmaceutical Technology · NCT07122401 · 424 planned · China
- Nov 23, 2025Phase 1 study in Hemodialysis Subjects With Secondary HyperparathyroidismShaanxi Micot Pharmaceutical Technology · NCT07284043 · 6 enrolled · China
Ahead
- Nov 26, 2026Primary completion: phase 3 study in Hyperparathyroidism, SecondaryShaanxi Micot Pharmaceutical Technology · NCT07122401
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07284043Hemodialysis Subjects With Secondary Hyperparathyroidism · China | 1 | Completed | Shaanxi Micot Pharmaceutical Technology | May 14, 2026 | 6 |
| NCT07122401Hyperparathyroidism, Secondary · China | 3 | Recruiting | Shaanxi Micot Pharmaceutical Technology | Nov 26, 2026 | 424 |
| NCT06976177Hyperparathyroidism, Secondary · China | 2 | Recruiting | Shaanxi Micot Technology | Aug 19, 2025 | 310 |
| NCT06747247Hyperparathyroidism, Secondary · China | 2 | Completed | Shaanxi Micot Pharmaceutical Technology | May 12, 2025 | 98 |
| NCT06690242Hyperparathyroidism, Secondary · China | 2 | Completed | Shaanxi Micot Pharmaceutical Technology | Aug 30, 2025 | 115 |
| NCT04783090Healthy Volunteer · United States | 1 | Completed | Shaanxi Micot Technology | Dec 31, 2021 | 40 |
How it is read
Names in the registry
- “MT1013”, 5 entries
- “[14C] MT1013/MT1013 Injection”, 2 entries
- “Single ascending doses of MT1013”, 1 entry
- “Multiple ascending doses of MT1013”, 1 entry
Codes read as this program: MT1013.
Conditions, from the studies’ own filings
- Hyperparathyroidism, Secondary, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.